Outlook Therapeutics (OTLK) Reports Positive Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Outlook Therapeutics, Inc. (OTLK) Phase 3 Data Supports Approval - Analyst
August 3, 2021 11:54 AM EDTEarlier today, Outlook Therapeutics, Inc. (NASDAQ: OTLK) announced positive clinical and highly statistically significant top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010 / LYTENAVA (bevacizumab) - the companys lead drug candidate for treatment of neovascular... More
Outlook Therapeutics Incs. (OTLK) PT Raised to $6 at H.C. Wainwright
August 3, 2021 10:56 AM EDTH.C. Wainwright analyst Douglas Tsao raised the price target on Outlook Therapeutics Incs. (NASDAQ: OTLK) to $6.00 (from $5.00) while maintaining a Buy rating.
... MoreOutlook Therapeutics (OTLK) Climbs 41%
August 3, 2021 7:43 AM EDTOutlook Therapeutics (NASDAQ: OTLK) Climbs 41%
Earlier Outlook Therapeutics (OTLK) Reports Positive Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010... More